MX2021006864A - Anticuerpos contra el factor c2b del complemento humano y metodos de uso. - Google Patents
Anticuerpos contra el factor c2b del complemento humano y metodos de uso.Info
- Publication number
- MX2021006864A MX2021006864A MX2021006864A MX2021006864A MX2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- binding fragments
- human
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779102P | 2018-12-13 | 2018-12-13 | |
| PCT/IB2019/060802 WO2020121282A1 (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006864A true MX2021006864A (es) | 2021-07-02 |
Family
ID=69143627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006864A MX2021006864A (es) | 2018-12-13 | 2019-12-13 | Anticuerpos contra el factor c2b del complemento humano y metodos de uso. |
| MX2025010337A MX2025010337A (es) | 2018-12-13 | 2021-06-10 | Anticuerpos contra el factor c2b del complemento humano y metodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010337A MX2025010337A (es) | 2018-12-13 | 2021-06-10 | Anticuerpos contra el factor c2b del complemento humano y metodos de uso |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11161900B2 (https=) |
| EP (2) | EP3893924B1 (https=) |
| JP (3) | JP7110491B2 (https=) |
| KR (2) | KR20250030005A (https=) |
| CN (2) | CN113260375B (https=) |
| AU (3) | AU2019397614B2 (https=) |
| BR (1) | BR112021011107A2 (https=) |
| CA (1) | CA3119655A1 (https=) |
| DK (1) | DK3893924T3 (https=) |
| EA (1) | EA202191658A1 (https=) |
| ES (1) | ES2991894T3 (https=) |
| FI (1) | FI3893924T3 (https=) |
| HU (1) | HUE068993T2 (https=) |
| IL (2) | IL283916B2 (https=) |
| LT (1) | LT3893924T (https=) |
| MX (2) | MX2021006864A (https=) |
| PL (1) | PL3893924T3 (https=) |
| PT (1) | PT3893924T (https=) |
| SG (1) | SG11202105195PA (https=) |
| WO (1) | WO2020121282A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113260375B (zh) * | 2018-12-13 | 2024-10-01 | 阿尔金克斯有限公司 | 针对人补体因子C2b的抗体及使用方法 |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
| WO2025260123A1 (en) * | 2024-06-17 | 2025-12-26 | CSL Innovation Pty Ltd | Anti-c2 antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| EP2073898A1 (en) | 2006-10-10 | 2009-07-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement inhibition for improved nerve regeneration |
| RU2474588C2 (ru) * | 2008-05-05 | 2013-02-10 | Новиммун Са | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| SG186397A1 (en) * | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| HUE049154T2 (hu) * | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| CA2847862C (en) | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2997045A4 (en) | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| ES2904709T3 (es) | 2013-05-23 | 2022-04-05 | Broteio Pharma B V | Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas |
| CA2859114A1 (en) | 2013-08-29 | 2015-02-28 | International Automotive Components Group North America, Inc. | Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof |
| SI3052192T1 (sl) * | 2013-10-02 | 2020-11-30 | Medimmune, Llc | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe |
| JP2016539919A (ja) * | 2013-10-17 | 2016-12-22 | オメロス コーポレーション | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| SI3215527T1 (sl) | 2014-11-05 | 2025-04-30 | Annexon, Inc. | Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba |
| BR112018010279A2 (pt) | 2015-11-19 | 2019-02-05 | Abbvie Stemcentrx Llc | novos anticorpos anti-emr2 e métodos de uso |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| WO2017132259A1 (en) | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| AU2017213117A1 (en) | 2016-01-27 | 2018-07-19 | CSL Behring Lengnau AG | Recombinant IgG Fc multimers |
| US20190151414A1 (en) | 2016-05-10 | 2019-05-23 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| WO2018107109A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CR20190468A (es) | 2017-03-14 | 2019-12-17 | Bioverativ Usa Inc | Métodos para tratar enfermedades y trastornos mediados por completo |
| CN110506056A (zh) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体和其使用方法 |
| SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| CN113260375B (zh) * | 2018-12-13 | 2024-10-01 | 阿尔金克斯有限公司 | 针对人补体因子C2b的抗体及使用方法 |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2019
- 2019-12-13 CN CN201980082826.8A patent/CN113260375B/zh active Active
- 2019-12-13 PL PL19832737.1T patent/PL3893924T3/pl unknown
- 2019-12-13 DK DK19832737.1T patent/DK3893924T3/da active
- 2019-12-13 EP EP19832737.1A patent/EP3893924B1/en active Active
- 2019-12-13 FI FIEP19832737.1T patent/FI3893924T3/fi active
- 2019-12-13 LT LTEPPCT/IB2019/060802T patent/LT3893924T/lt unknown
- 2019-12-13 SG SG11202105195PA patent/SG11202105195PA/en unknown
- 2019-12-13 JP JP2021533300A patent/JP7110491B2/ja active Active
- 2019-12-13 WO PCT/IB2019/060802 patent/WO2020121282A1/en not_active Ceased
- 2019-12-13 MX MX2021006864A patent/MX2021006864A/es unknown
- 2019-12-13 PT PT198327371T patent/PT3893924T/pt unknown
- 2019-12-13 KR KR1020257005663A patent/KR20250030005A/ko active Pending
- 2019-12-13 EA EA202191658A patent/EA202191658A1/ru unknown
- 2019-12-13 EP EP24164880.7A patent/EP4375297A3/en active Pending
- 2019-12-13 IL IL283916A patent/IL283916B2/en unknown
- 2019-12-13 KR KR1020217021353A patent/KR102774146B1/ko active Active
- 2019-12-13 IL IL319975A patent/IL319975A/en unknown
- 2019-12-13 CA CA3119655A patent/CA3119655A1/en active Pending
- 2019-12-13 HU HUE19832737A patent/HUE068993T2/hu unknown
- 2019-12-13 ES ES19832737T patent/ES2991894T3/es active Active
- 2019-12-13 CN CN202411410387.8A patent/CN119371526A/zh active Pending
- 2019-12-13 US US16/714,264 patent/US11161900B2/en active Active
- 2019-12-13 AU AU2019397614A patent/AU2019397614B2/en active Active
- 2019-12-13 BR BR112021011107A patent/BR112021011107A2/pt unknown
-
2021
- 2021-06-10 MX MX2025010337A patent/MX2025010337A/es unknown
- 2021-10-01 US US17/491,656 patent/US11591386B2/en active Active
-
2022
- 2022-01-10 US US17/572,518 patent/US11708403B2/en active Active
- 2022-07-20 JP JP2022115252A patent/JP7611191B2/ja active Active
- 2022-12-15 AU AU2022287637A patent/AU2022287637B2/en active Active
-
2023
- 2023-06-07 US US18/330,903 patent/US20240002484A1/en active Pending
-
2024
- 2024-08-01 JP JP2024125608A patent/JP2024160274A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252632A patent/AU2025252632A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010337A (es) | Anticuerpos contra el factor c2b del complemento humano y metodos de uso | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| PH12019502755A1 (en) | Antibodies that specifically bind pd-1 and methods of use | |
| ZA202100676B (en) | Anti-tigit antibody and uses thereof | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EP4275698A3 (en) | Anti-tigit antibodies and methods of use thereof | |
| MY185813A (en) | Factor xi antibodies and methods of use | |
| EA202090275A2 (ru) | Антитела против с5 с улучшенными фармакокинетическими характеристиками | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| EA201892774A1 (ru) | Антитела | |
| WO2016154003A8 (en) | Neutralizing antibodies to gp120 and their use | |
| MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| NZ700856A (en) | St2 antigen binding proteins | |
| EA201590138A1 (ru) | Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| NZ717399A (en) | Antibodies against csf-1r | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| MX2018001964A (es) | Polipeptidos mrka, anticuerpos y usos de los mismos. | |
| TN2016000569A1 (en) | Anti-il4-il 13 bispecific antibodies | |
| EA201591898A1 (ru) | Антитела, направленные на m-csf |